Myelodysplastic Syndrome Drugs Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the myelodysplastic syndrome drugs market grown in recent years?
Over the past years, there has been significant growth in the market for drugs treating myelodysplastic syndrome. The market, which is forecasted to increase from $2.25 billion in 2024 to $2.47 billion in 2025, is expected to witness a compound annual growth rate (CAGR) of 9.8%. Factors contributing to the growth throughout the historical period include a rising elderly population, advances in diagnostic techniques, cases of MDS related to chemotherapy, a growing number of cancer survivors, and progress in clinical research and drug development.
How is the myelodysplastic syndrome drugs market size expected to evolve during the forecast period?
In the coming years, the market for myelodysplastic syndrome drugs is predicted to witness robust growth, and it is projected to swell to “$3.58 billion by 2029 with a compound annual growth rate (CAGR) of 9.7%. This anticipated growth during the forecast period can be credited to a rising elderly population, breakthroughs in targeted therapies, a deeper understanding of disease processes, heightened awareness and early detection, and the broadening of oncology research. Key trends expected during this forecast period comprise optimization of erythropoiesis-stimulating agents, blended therapies, a growing emphasis on iron chelation therapy, regulatory approvals and market entry, and patient-focused care models.
Get your myelodysplastic syndrome drugs market report here!
Which key drivers are propelling the myelodysplastic syndrome drugs market’s growth?
The rise in the occurrence of myelodysplastic syndrome is anticipated to boost the myelodysplastic syndrome drug market’s expansion in the forthcoming years. Myelodysplastic syndrome (MDS) comprises a set of disorders marked by anomalous development and maturation of blood cells in the bone marrow. It’s a specific kind of blood cancer that heavily affects the generation of healthy blood cells. Drugs used in the treatment of myelodysplastic syndrome are often intended to deter or adjust the immune system, reducing the need for red blood cell transfers. For example, a publication in the American Journal of Managed Care in October 2022 reported that the number of myelodysplastic syndrome cases in the United States is estimated to range from 60,000 to 175,000. Consequently, a surge in myelodysplastic syndrome instances is propelling the growth of its drug market.
What are the market segments in the myelodysplastic syndrome drugs industry?
The myelodysplastic syndrome drugs market covered in this report is segmented –
1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Immunomodulatory Drugs: Thalidomide, Lenalidomide, Pomalidomide
2) By Hypomethylating Agents: Azacitidine, Decitabine, Guadecitabine
3) By Anti-anemics: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion Products
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10675&type=smp
Which leading companies are shaping the growth of the myelodysplastic syndrome drugs market?
Major companies operating in the myelodysplastic syndrome drugs market include Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.
What key trends are currently impacting the myelodysplastic syndrome drugs market’s development?
Leading organizations in the myelodysplastic syndrome drugs market are focusing their efforts on the creation of telomerase inhibitors to aim at the telomerase enzyme, with the goal of slowing the disease’s progression by constraining the unchecked proliferation of abnormal cells. Telomerase inhibitors prove valuable in the sphere of myelodysplastic syndrome drugs as they act by curbing the telomerase enzyme, thus reducing the spread of unusual cells, and possibly enhancing patients’ results. For instance, in June 2024, Geron Corporation, an American biotechnology firm, introduced rytelo (imetelstat), an FDA-approved intravenous telomerase inhibitor catered to adults suffering from low to intermediate-1 risk myelodysplastic syndromes (LR-MDS) and transfusion-dependent anemia that doesn’t respond or is not eligible for ESA. With a manageable safety profile, Rytelo provides long-lasting transfusion independence, improved hemoglobin counts, and meets a previously unaddressed need in the myelodysplastic syndrome drugs market.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10675
Which geographic areas are influencing the growth of the myelodysplastic syndrome drugs market?
North America was the largest region in the Myelodysplastic syndrome drugs market in 2024.Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Dermatology Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report
Respiratory Diseases Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report
Gastrointestinal Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
